186 related articles for article (PubMed ID: 20194893)
1. Efficacy of single-agent lenalidomide in patients with JAK2 (V617F) mutated refractory anemia with ring sideroblasts and thrombocytosis.
Huls G; Mulder AB; Rosati S; van de Loosdrecht AA; Vellenga E; de Wolf JT
Blood; 2010 Jul; 116(2):180-2. PubMed ID: 20194893
[TBL] [Abstract][Full Text] [Related]
2. Refractory anemia with ring sideroblasts and RARS with thrombocytosis.
Patnaik MM; Tefferi A
Am J Hematol; 2015 Jun; 90(6):549-59. PubMed ID: 25899435
[TBL] [Abstract][Full Text] [Related]
3. Refractory anaemia with ringed sideroblasts associated with marked thrombocytosis (RARS-T) with superimposed 5q-syndrome.
Ziarkiewicz M; Dwilewicz-Trojaczek J; Pastwińska A; Chmarzyńska E; Paszkowska-Kowalewska M; Koperski Ł; Jędrzejczak WW; Ziarkiewicz-Wróblewska B
Pol J Pathol; 2010; 61(2):105-9. PubMed ID: 20924996
[TBL] [Abstract][Full Text] [Related]
4. Response to lenalidomide of a patient with t(2;3)(p23;q29) and JAK2 non-mutated refractory anemia with ring sideroblasts and thrombocytosis.
Zhang M; You Y; Li X; He Y; Zheng J; Li W; Zou P; Liu X; Liu F
Leuk Lymphoma; 2013 Jul; 54(7):1544-6. PubMed ID: 23252419
[No Abstract] [Full Text] [Related]
5. Development of refractory anemia with ring sideroblasts associated with thrombocytosis from pre-existing refractory anemia with ring sideroblasts through acquisition of Jak2 V617F mutation.
Lu CM; Zhou L; Wang E; Feng S; Sebastian S; Behler C
Leuk Lymphoma; 2011 Dec; 52(12):2405-7. PubMed ID: 21806348
[No Abstract] [Full Text] [Related]
6. JAK2V617F mutation status identifies subtypes of refractory anemia with ringed sideroblasts associated with marked thrombocytosis.
Schmitt-Graeff AH; Teo SS; Olschewski M; Schaub F; Haxelmans S; Kirn A; Reinecke P; Germing U; Skoda RC
Haematologica; 2008 Jan; 93(1):34-40. PubMed ID: 18166783
[TBL] [Abstract][Full Text] [Related]
7. Refractory anemia with ringed sideroblasts and thrombocytosis without JAK2 V617F mutation: report of three cases.
Tatic A; Vasilică M; Coliţă A; Vasilache D; Dobrea C; Jardan C; Găman AM; Crişan AM; Coliţă D; Coriu D
Rom J Morphol Embryol; 2013; 54(4):1177-82. PubMed ID: 24399021
[TBL] [Abstract][Full Text] [Related]
8. Occurrence of the JAK2 V617F mutation in the WHO provisional entity: myelodysplastic/myeloproliferative disease, unclassifiable-refractory anemia with ringed sideroblasts associated with marked thrombocytosis.
Remacha AF; Nomdedéu JF; Puget G; Estivill C; Sarda MP; Canals C; Aventin A
Haematologica; 2006 May; 91(5):719-20. PubMed ID: 16670082
[TBL] [Abstract][Full Text] [Related]
9. Prognostic interaction between thrombocytosis and JAK2 V617F mutation in the WHO subcategories of myelodysplastic/myeloproliferative disease-unclassifiable and refractory anemia with ringed sideroblasts and marked thrombocytosis.
Atallah E; Nussenzveig R; Yin CC; Bueso-Ramos C; Tam C; Manshouri T; Pierce S; Kantarjian H; Verstovsek S
Leukemia; 2008 Jun; 22(6):1295-8. PubMed ID: 18059483
[No Abstract] [Full Text] [Related]
10. Age, JAK2(V617F) and SF3B1 mutations are the main predicting factors for survival in refractory anaemia with ring sideroblasts and marked thrombocytosis.
Broséus J; Alpermann T; Wulfert M; Florensa Brichs L; Jeromin S; Lippert E; Rozman M; Lifermann F; Grossmann V; Haferlach T; Germing U; Luño E; Girodon F; Schnittger S;
Leukemia; 2013 Sep; 27(9):1826-31. PubMed ID: 23594705
[TBL] [Abstract][Full Text] [Related]
11. Refractory anemia with ringed sideroblasts associated with marked thrombocytosis (RARS-T), another myeloproliferative condition characterized by JAK2 V617F mutation.
Szpurka H; Tiu R; Murugesan G; Aboudola S; Hsi ED; Theil KS; Sekeres MA; Maciejewski JP
Blood; 2006 Oct; 108(7):2173-81. PubMed ID: 16741247
[TBL] [Abstract][Full Text] [Related]
12. High occurrence of JAK2 V617 mutation in refractory anemia with ringed sideroblasts associated with marked thrombocytosis.
Renneville A; Quesnel B; Charpentier A; Terriou L; Crinquette A; Laï JL; Cossement C; Lionne-Huyghe P; Rose C; Bauters F; Preudhomme C
Leukemia; 2006 Nov; 20(11):2067-70. PubMed ID: 16990759
[No Abstract] [Full Text] [Related]
13. Mutations of JAK2 and TET2, but not CBL are detectable in a high portion of patients with refractory anemia with ring sideroblasts and thrombocytosis.
Flach J; Dicker F; Schnittger S; Kohlmann A; Haferlach T; Haferlach C
Haematologica; 2010 Mar; 95(3):518-9. PubMed ID: 19903679
[No Abstract] [Full Text] [Related]
14. Clinical features and course of refractory anemia with ring sideroblasts associated with marked thrombocytosis.
Broseus J; Florensa L; Zipperer E; Schnittger S; Malcovati L; Richebourg S; Lippert E; Cermak J; Evans J; Mounier M; Raya JM; Bailly F; Gattermann N; Haferlach T; Garand R; Allou K; Besses C; Germing U; Haferlach C; Travaglino E; Luno E; Pinan MA; Arenillas L; Rozman M; Perez Sirvent ML; Favre B; Guy J; Alonso E; Ahwij N; Jerez A; Hermouet S; Maynadié M; Cazzola M; Girodon F
Haematologica; 2012 Jul; 97(7):1036-41. PubMed ID: 22532522
[TBL] [Abstract][Full Text] [Related]
15. Refractory anemia with ring sideroblasts associated with marked thrombocytosis: a mixed group exhibiting a spectrum of morphologic findings.
Gurevich I; Luthra R; Konoplev SN; Yin CC; Medeiros LJ; Lin P
Am J Clin Pathol; 2011 Mar; 135(3):398-403. PubMed ID: 21350094
[TBL] [Abstract][Full Text] [Related]
16. Refractory anemia with ring sideroblasts associated with marked thrombocytosis harboring cytogenetic abnormality dup(2)(p15p22) treated with decitabine.
Kim J; Kim YR; Lee KA
Leuk Lymphoma; 2012 Nov; 53(11):2287-9. PubMed ID: 22468921
[No Abstract] [Full Text] [Related]
17. Treatment outcomes for patients with myelodysplastic syndrome/myeloproliferative neoplasms with ring sideroblasts and thrombocytosis.
Komrokji R; Melody M; Al Ali N; Chan O; Klimek V; Ball BJ; Sekeres MA; Lucas G; Maciejewski JP; Sallman DA; Padron E; Kuykendall A; Lasho T; Al-Kali A; Naqvi K; Steensma DP; Garcia-Manero G; Patnaik MM
Leuk Lymphoma; 2022 Jan; 63(1):199-204. PubMed ID: 34448437
[TBL] [Abstract][Full Text] [Related]
18. Refractory anemia with ringed sideroblasts associated with thrombocytosis: comparative analysis of marked with non-marked thrombocytosis, and relationship with JAK2 V617F mutational status.
Raya JM; Arenillas L; Domingo A; Bellosillo B; Gutiérrez G; Luño E; Piñán MA; Barbón M; Pérez-Sirvent ML; Muruzábal MJ; Yánez L; García L; Lemes A; Navarro JT; Elosegi A; Cortés MA; Villegas A; Durán MA; Ardanaz M; Florensa L;
Int J Hematol; 2008 Nov; 88(4):387-395. PubMed ID: 18820995
[TBL] [Abstract][Full Text] [Related]
19. The JAK2 V617F mutation is rare in RARS but common in RARS-T.
Ceesay MM; Lea NC; Ingram W; Westwood NB; Gäken J; Mohamedali A; Cervera J; Germing U; Gattermann N; Giagounidis A; Garcia-Casado Z; Sanz G; Mufti GJ
Leukemia; 2006 Nov; 20(11):2060-1. PubMed ID: 16932338
[No Abstract] [Full Text] [Related]
20. Refractory anemia with ring sideroblasts.
Malcovati L; Cazzola M
Best Pract Res Clin Haematol; 2013 Dec; 26(4):377-85. PubMed ID: 24507814
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]